跳至主要内容
临床试验/NCT01561443
NCT01561443已完成不适用

LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer

AstraZeneca1 个研究点 分布在 1 个国家目标入组 153 人开始时间: 2012年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
153
试验地点
1
主要终点
Collection of data of routine regimens of hormone therapy in postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer

研究概览

简要总结

This is the first study focused on features/stereotypes of the first and second-line treatment patterns in Russia, comparison of different treatments, and determination of effective hormone treatment patterns in real-life practice with evaluation of pharmacoeconomic aspects. Study LINE is designed for collection of data on clinical effectiveness of second-line hormone treatment and quality of life in patients with breast cancer(BC).

详细描述

LINE: Treatment patterns in postmenopausaL women wIth hormone receptor positive breast caNcEr

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
Female
接受健康志愿者

入选标准

  • Postmenopausal women with hormone receptor-positive breast cancer:
  • Recurrence after the adjuvant hormone therapy;
  • Or initially inoperable locally advanced or metastatic breast cancer progressed after the first line hormone therapy;
  • Ability to read and write and complete questionnaires Provision of written informed consent
  • Patients who have already been prescribed therapy with the above-mentioned lines and who can continue on the prescribed therapy in the investigator's opinion according to his/her regular clinical practice and cure

排除标准

  • As per study design, to ensure high validity of data and to obtain accurate information on real-life practice,
  • Patients currently participating in other clinical studies will not be included in this study

结局指标

主要结局

Collection of data of routine regimens of hormone therapy in postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer

时间窗: 2 years

次要结局

  • Quality of life (QoL): the extent of reduction in QoL deficit from 1 visit(2 years)
  • Historical data analysis: treatment patterns effectiveness, duration of the adjuvant or first-line hormone treatment(2 years)
  • Co-morbidities and relevant historical data(2 years)
  • The information on spontaneous office visit to oncologist or hospitalization including reasons, diagnosis, days of hospitalization, procedures and concomitant medication changes will be collected.(2 years)
  • Performance status (ECOG)(2 years)
  • The extent of reduction anxiety inventory(2 years)
  • Response duration(2 years)
  • Effectiveness: Tumor regression; number of patients with complete response (CR), partial response (PR) or stable disease(2 years)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

LINE: Treatment Patterns in postmenopausaL Women... | 临床试验